Enanta Pharmaceuticals (ENTA) said Thursday that a phase 2a study evaluating EDP-323 in adults with respiratory syncytial virus, or RSV, met its primary and secondary endpoints.
Reductions of 85% to 87% in viral load area under the curve, 97% to 98% in infectious viral load AUC, and 66% to 78% in overall symptoms were observed across the trial, Enanta said. All endpoints were met with "highly statistically significant" results, the company added.
The company also said EDP-323 was observed to be generally safe and well-tolerated, with no serious or severe adverse events, over a five-day dosing period and through 28 days of follow-up.
Shares of the company were up 3.2% in recent premarket activity.
Price: 11.01, Change: +0.34, Percent Change: +3.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.